New Clinical Trial

November 1st, 2012

A randomized, double blind, 12 week, parallel group, placebo controlled study of the efficacy and safety of RO4917523 in patients with Fragile X Syndrome Identifier: NCT01517698

This international multi-centre trial, run by Roche, aims to evaluate a new medication, RO4917523, for people aged 16-50 with Fragile X Syndrome. The Patrick Wild Centre is leading the research in the UK.  There are three Scottish sites (Lothian, Glasgow and Tayside) which are now recruiting and other UK sites are planned.

Please contact Dr Andrew Stanfield if you would like more details.

Read more about Ongoing Treatment Trials by clicking here.

Accessibility Statement | Site Map | Privacy

© Copyright The Patrick Wild Centre | All rights reserved
The University of Edinburgh is a charity registered in Scotland, No: SC005336

2017 | Website by Heehaw Digital